Expand KTTA Menu
KTTA MENU

KTTA Latest Press Releases

-- July 21, 2026 --

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026 Globe Newswire 7:00 AM

-- July 8, 2026 --

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit Globe Newswire 7:02 AM

-- June 30, 2026 --

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion Globe Newswire 7:00 AM

-- June 16, 2026 --

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial Globe Newswire 7:00 AM

-- June 15, 2026 --

Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference Globe Newswire 7:02 AM

-- June 2, 2026 --

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Globe Newswire 7:02 AM

-- May 4, 2026 --

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer Globe Newswire 7:01 AM

-- April 20, 2026 --

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Globe Newswire 7:01 AM

-- April 1, 2026 --

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity Globe Newswire 7:01 AM
Market Data Delayed 15 Minutes